Research
Novel siRNA Therapeutic Cuts Liver Fat in MASLD, Early Trial Shows
The Brief
- A single dose of the siRNA therapy CIDEBsiRNA (also known as ALN-CIDEB) led to normal liver fat content in most patients with MASLD in an early trial.
- In the same patients, the therapy lowered alanine aminotransferase (ALT) levels.
- The results come from an early-stage trial reported at an AASLD meeting, so they are preliminary.
Why it matters
It is an early sign that silencing the CIDEB gene with siRNA may reduce liver fat in MASLD, a common liver condition with few approved drug treatments. Larger, longer trials are needed before it affects clinical practice.
Who’s affected
- hepatologists and clinicians treating metabolic dysfunction-associated steatotic liver disease (MASLD)
- patients with MASLD and researchers in liver disease and RNA therapeutics
- #masld
- #sirna
- #liver fat
- #clinical trial
- #liver disease
(MedPage Today) -- One dose of a novel small interfering RNA (siRNA) therapy -- CIDEBsiRNA (also known as ALN-CIDEB) -- led to normal liver fat content and lower alanine aminotransferase (ALT) levels in most patients with metabolic dysfunction...